The RNA-binding protein Musashi 1 stabilizes tachykinin mRNA in breast cancer cells, increasing substance P neuropeptide production and promoting tumor growth.
Msi1 knockdown significantly reduced tumor growthWhen Musashi 1 was removed from breast cancer cells, tumors in mice grew significantly less, demonstrating that the Msi1-driven substance P production pathway is functionally important for cancer progression.
What the researchers found
Musashi 1 (Msi1) binds to the 3' UTR of TAC1 mRNA in breast cancer cells, competing with microRNAs miR130a and miR206 to stabilize TAC1 mRNA and enhance its translation, thereby promoting tumor growth. Knockdown of Msi1 in breast cancer cells significantly reduced tumor growth in nude BALB/c mice.
Why it matters
Understanding how Musashi 1 stabilizes TAC1 mRNA reveals a novel regulatory mechanism in breast cancer progression, which could lead to new therapeutic targets to inhibit tumor growth.
How the study worked
The study used in vitro translational assays, mRNA stabilization analyses, protein-RNA interaction assays including RNA-shift and RNA supershift analyses, proteomic identification, reporter gene systems, and in vivo tumor growth experiments in nude BALB/c mice injected with Msi1-knockdown breast cancer cells.
What this study cannot tell us
The exact clinical relevance and therapeutic potential require further validation in human studies, and the study did not specify the sample size or provide detailed quantitative data on Msi1 expression levels in patient tumors.
How to read the evidence
This is a preclinical mechanistic study using breast cancer cell lines and a mouse xenograft model. While it identifies a novel molecular mechanism, clinical relevance requires human tumor validation.
When this study was published
Published in 2016, this study established a novel mechanism linking RNA-binding proteins to neuropeptide-driven cancer growth. Subsequent research may have built on this Msi1-TAC1 axis discovery.
The bigger picture
The role of neuropeptides in cancer is an emerging and important field. Substance P, traditionally studied for pain and inflammation, is increasingly recognized as a cancer growth factor. This study reveals the molecular machinery that cancer cells use to overproduce substance P, opening the door to targeting the Msi1-TAC1 axis therapeutically. Understanding how neuropeptide signaling intersects with cancer biology could lead to entirely new treatment approaches.
Questions still open
- Could Msi1 inhibitors reduce substance P-driven tumor growth in breast cancer patients?
- Is the Msi1-TAC1 axis also active in other cancer types known to overexpress substance P?
- Would combining Msi1 inhibition with neurokinin receptor antagonists produce synergistic anti-tumor effects?
Common questions
What is substance P and why does it matter in cancer?
Could this lead to new breast cancer treatments?
Read the original research
The RNA-binding protein Musashi 1 stabilizes the oncotachykinin 1 mRNA in breast cancer cells to promote cell growth.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 30(1), 149-59
Citation
Nahas, George R; Murthy, Raghav G; Patel, Shyam A; Ganta, Teja; Greco, Steven J; Rameshwar, Pranela. (2016). The RNA-binding protein Musashi 1 stabilizes the oncotachykinin 1 mRNA in breast cancer cells to promote cell growth.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 30(1), 149-59. https://doi.org/10.1096/fj.15-278770